"The pharmacist remains a very important member of the healthcare team that has the ability to explain to the patient the differences between the biologic and the biosimilar. It is the pharmacist–patient relationship that will assist the patient in making the best decisions to obtain the optimal clinical outcome," said Larry D. Wagenknecht, PharmD, FMPA, FAPhA, CEO of the Michigan Pharmacists Association.
Recently, Michigan Governor, Republican Rick Snyder, signed into effect legislation that creates a pathway for the substitution of FDA-designated interchangeable biosimilars for their reference products at the pharmacy level. The Center for Biosimilars® interviewed Larry D. Wagenknecht, PharmD, FMPA, FAPhA, CEO of the Michigan Pharmacists Association on his organization’s stance on the new law.
When asked if his organization supported the bill, Wagenknecht said in an email, “The Michigan Pharmacists Association did end up supporting the legislation after some changes were made to the prescriber notification section of the bill.” He added that the Association wants to ensure that the law does not create any undue barriers in providing patients with access to the best options that will treat their conditions.
Currently, there are no FDA-approved interchangeable biosimilars, nor has any drug maker sought such a designation for a biosimilar product. With respect to the rationale for passing legislation dealing with interchangeable biosimilars now, Wagenknecht said the move was in preparation for the future: “The benefit of passing the bill now [March 2018] is minimal since the opportunity for substitution of a biosimilar really isn’t an option today. However, with the medications in the biosimilar pipeline, there will likely be opportunities in the coming years."
It remains unclear whether legislation passed concerning the substitution of interchangeable biosimilars, which has been passed or considered in numerous other states, such as South Dakota and Wisconsin in the early months of this year, will have any impact on uptake amongst prescribers of biosimilar medicines.
Wagenknecht said, “[The prescribing of biosimilars] is very difficult to predict. Biosimilar medications tend to treat more complicated medical conditions, so having a law on the books is not going to increase the use of biosimilar medications. The economics of healthcare will push for the use of biosimilars once they are available.”
Asked if members of his organization dispense biosimilars now, Wagenknecht said, “Our members do dispense biologics, and since the opportunity of dispensing biosimilars is not prevalent, we really don’t know how patients are going to respond. The pharmacist remains a very important member of the healthcare team that has the ability to explain to the patient the differences between the biologic and the biosimilar. It is the pharmacist—patient relationship that will assist the patient in making the best decisions to obtain the optimal clinical outcome.”
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.